A novel combined score of biomarkers in sputum may be an indicator for lung cancer: A pilot study.
Lung cancer is a leading cause of morbidity and mortality worldwide and there is an urgent need for sensitive, specific, and reliable biomarkers. The study population included 60 patients (31 with lung cancer and 29 with chronic obstructive pulmonary disease [COPD]) and thirty healthy individuals comprised the control group. Measurements of neutrophil, beclin-1, VEGF, ICAM, VCAM, and TNF-alpha levels in induced sputum were analyzed as possible biomarkers for lung cancer. Neutrophil, beclin-1, VEGF, ICAM and TNF-alpha levels of lung cancer patients differed significantly compared to those of COPD patients and healthy controls. A novel combined-score was created which was found to increase the likelihood to belong to the cancer group by 70% (odds-ratio 1.70 CI = 1.310-2.224,p < 0.001). Biomarkers of autophagy, angiogenesis and inflammation in lung-cancer patients are significantly different from controls, and combination of these markers may be an indicator for lung cancer.